On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

Boys and young adult male patients with congenital adrenal hyperplasia receiving glucocorticoid treatment have lower bone ...

The Research Topic has been launched recently. Authors will be published on this page as soon as they become available.

For the first time ever, the FDA has approved a treatment specifically for people with classic congenital adrenal hyperplasia (CAH), a genetic condition that affects the adrenal glands.

Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Free Report) have been given an average recommendation of “Hold” by the six ratings firms that are currently covering the stock, Marketbeat ...

In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...

HBM Alpha Therapeutics Inc. signed a potential $395 million licensing deal Feb. 26 with an unnamed “business partner” for its endocrine asset, HAT-001, adding another contender to the congenital ...